Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

Biochemical Pharmacology(2021)10.1016/j.bcp.2021.114516Source: DataRank Database

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs is a research paper published in Biochemical Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

nct pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 2.44)OA: greenTopics (41)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Tai‐Ho Hung ORCID,Sabrina Lusvarghi ORCID,Yi-Hsuan Chu,Sung-Han Hsiao,Yang-Hui Huang

Live enrichment

PubMed:33713643 PMC:PMC8291035 OpenAlex:https://openalex.org/W3137711059

Intramural NIH HHS

Grant: Z01 BC010030

FWCI

2.44

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8291035

publisherhttps://api.elsevier.com/content/article/PII:S000629522100112X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S000629522100112X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bcp.2021.114516

Fields of Study

Drug Transport and Resistance MechanismsCancer therapeutics and mechanismsRadiopharmaceutical Chemistry and Applications

MeSH Terms

AcrylamidesAntineoplastic AgentsCell SurvivalDose-Response Relationship, DrugHumansIndolesPyrimidinesGene Expression Regulation, NeoplasticProtein Structure, SecondaryDrug Resistance, MultipleATP Binding Cassette Transporter, Subfamily BDrug Resistance, NeoplasmCell Line, TumorHEK293 CellsErbB Receptors

Keywords

Abcg2Multiple drug resistancePharmacologyT790MATP-binding cassette transporterCancer cellCancerEGFR inhibitorsTyrosine-kinase inhibitorDrug resistanceP-glycoproteinCancer researchMedicineEpidermal growth factor receptorBiologyTransporterInternal medicineGefitinibBiochemistryMultidrug resistanceAbcb1AlmonertinibHs-10296

Sustainable Development Goals

SDG 0: Good health and well-being

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

FAIR Checklist

Authors (8)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)